Based on the results, we propose a novel immunophenotypic classification of HCCs that facilitates prognostic prediction and may support decision making with regard to the choice of therapy.

Hepatocellular ... detection tool for liver cancer (39). In a recent study, Nguyen et al. used concurrent analysis of cancer-related mutations and fragment length profiles to discriminate mutation ...

Objective To characterise gut microbiome in patients with hepatocellular carcinoma (HCC) and evaluate the potential ... and the POD based on the 30 OTUs markers achieved powerful classification ...

Background: Currently, inoperable hepatocellular carcinoma (HCC) is treated by both transarterial ... The mRECIST criteria were used to evaluate treatment response rates (10). The detailed ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...

On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

Breast cancers can be classified into subgroups that hint at the aggressiveness of the cancer and the likelihood that the ...